Sign in

CIK 0001395937

  • Large accelerated filer

Syndax Pharmaceuticals Inc

Sign in to watch
Ticker
SNDX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
320162505
Phone
+1 781-419-1400
Business address
730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, 10017
  1. 4 Open-market sale Chief Financial Officer sold 577 shares at $22.31 ($12,873)
  2. 4 Planned sale Director sold 52,855 shares at $21.18 ($1,119,421)
  3. 4 Planned sale Director sold 52,855 shares at $21.41 ($1,131,478)
  4. 4 Planned sale Director sold 52,855 shares at $19.53 ($1,032,237)
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Open-market sale President, Head of R&D sold 52,854 shares at $22.53 ($1,190,674)
  8. 4 Open-market sale Chief Scientific Officer sold 25,000 shares at $25.84 ($646,093)
  9. 4 Open-market sale Chief Executive Officer sold 5,959 shares at $27.64 ($164,697)
  10. 4 Open-market sale President, Head of R&D sold 52,854 shares at $26.83 ($1,417,909)
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Open-market sale Chief Scientific Officer sold 69 shares at $28.43 ($1,962)
  16. 4 Derivatives Options or other derivatives
  17. 4 Grant or award Director acquired 32,000 shares (grant or award)
  18. 4 Grant or award Director acquired 16,000 shares (grant or award)
  19. 4 Grant or award Director acquired 16,000 shares (grant or award)
  20. 4 Grant or award Director acquired 16,000 shares (grant or award)

Page 4 of 13 · 259 filings